vimarsana.com
Home
Live Updates
Eisai to Divest Rights for Anti-Epileptic Drug Fycompa (perampanel) CIII in United States to Catalyst Pharmaceuticals : comparemela.com
Eisai to Divest Rights for Anti-Epileptic Drug Fycompa (perampanel) CIII in United States to Catalyst Pharmaceuticals
TOKYO, Dec 20, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an agreement to transfer the United States (U.S.) commercial rights for the anti-epileptic drug (AED) Fycompa
Related Keywords
Tokyo ,
Japan ,
United States ,
Canada ,
Christopher Vancheri ,
Catalyst Pharmaceuticals ,
Eisai Inc ,
Eisai Co Ltd ,
Us Food Drug Administration ,
Catalyst Pharmaceuticals Inc ,
Global Health ,
Public Relations Department ,
Health Canada ,
Pharmaceutical New Drug Application ,
Drug Administration ,
Relations Department ,
Eisai ,
Givest ,
Tights ,
Anti ,
Epileptic ,
Drug ,
Ycompa ,
Perampanel ,
Iii ,
United ,
States ,
Catalyst ,
Pharmaceuticals ,
comparemela.com © 2020. All Rights Reserved.